Compare Incyte Corporation (INCY) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Public Storage — how do they compare? Incyte Corporation trades at $120.5 (market cap $24.54B), while Public Storage trades at $323.1 (market cap $60.71B). The key difference: Public Storage is far larger — about 2.5× Incyte Corporation's market cap, and Public Storage pays a 3.69% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PSA | |
|---|---|---|
Market Cap | $24.54B | $60.71B |
Sector | Health | Real Estate |
52-Week High | $129.93 | $330.47 |
52-Week Low | $81.61 | $258.44 |
Enterprise Value | $20.04B | $74.98B |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Public Storage (PSA) trades at $325.71, down 0.82% on the day, with a bullish technical outlook supported by moving averages. The REIT maintains strong profitability with 41.8% net income margin and has beaten earnings estimates for three consecutive quarters. Recent developments include the completed acquisition of National Storage Affiliates and consistent $3.00 quarterly dividends, positioning the company for growth through expansion and operational efficiency.
PSA presents a mixed investment case with premium valuation metrics (P/E 31.02) offset by strong fundamentals and growth initiatives. The consensus price target of $333.88 suggests modest upside potential, though elevated P/E and P/B ratios warrant caution. Key risks include interest rate sensitivity and integration challenges from recent acquisitions, while the stable dividend and expansion into Canada provide growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
